The financials
Zymeworks Inc. by the numbers
Zymeworks Inc. (ZYME) reported revenue of $2.4M in Q1 2026 (quarter ended March 31, 2026), down 91% from the same quarter a year earlier. That came with net loss of $44M. For the full year FY2025, revenue was $106M (+39% year on year) and net income −$81M. Its largest product in 2026-Q1 was Royalty at $1.3M, 61% of the disclosed total, just ahead of Research Support Payments And Other Service at 18%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $2.4M | $27M | −91% |
| Operating income | −$47M | −$26M | n/a |
| Net income | −$44M | −$23M | n/a |
| Diluted EPS | −$0.59 | −$0.30 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Royalty | $1.3M | 61% |
| Research Support Payments And Other Service | $392K | 18% |
| Drug Supply For Ongoing Studies | $345K | 16% |
| Drug Supply | $117K | 5.4% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $2.2M (-12%)
Royalty grew +558% year on yearMilestone -100% year on year
Segment Latestquarter on quarteryear on year
- Royalty$1.3M$1.3MQoQ +60%year on year +558%+60%+558%
- Research Support Payments And Other Service$392.0K$392.0KQoQ +11%year on year -91%+11%-91%
- Drug Supply For Ongoing Studies$345.0K$345.0KQoQ -64%year on year -88%-64%-88%
- Drug Supply$117.0K$117.0KQoQ +65%year on year -95%+65%-95%
- Deferred--QoQ -year on year ---
- Milestone$0.00$0.00QoQ -year on year -100%--100%
- Option Exercise Fee--QoQ -year on year ---
- Research Period Extension Fee--QoQ -year on year ---